Harness Dickey
  • People
  • Global IP Services
    • Practice Areas
    • Industries
    • Case Studies
  • Blog
  • News & Awards
  • About Us
    • Careers
    • Offices
  • IP Atlas
  • Contact Us
  • Client Login

Blog

Subscribe to our Blogs

  • Subscribe to our Blogs

Our business model is to cultivate lawyers who know all there is to know about intellectual property, whether it be special requirements under the America Invents Act (AIA), patenting chemical compositions and pharmaceuticals, current developments in software patenting, or combating “bad patents” in federal court litigation.  Lawyers from our various practice groups enjoy sharing their views in our blogs. Please join our audience and help us enrich the discussion. We welcome your participation and insight.

  • Chemistry & Nanotechnology

      ALL CATEGORIES

      • Biologics & Biosimilars
        • Competitor Dynamics
        • FDA Guidance & Updates
        • Interchangeability
      • BioPharma
      • Chemistry & Nanotechnology
      • Featured
      • Harnessing the Lessons of IP
      • IP Management
      • IPR-PGR
      • Licensing
      • Litigation
      • Patent Prosecution
      • Trademarks
  • All Years
    • 2018
    • 2017
    • 2016
    • 2015
    • 2014
    • 2013
    • 2012
    • 2011
    • 2010
    • 2009
  • Authors
    • John H. Ambrose, Jr.John H. Ambrose, Jr. 2
    • Tyson B. BensonTyson B. Benson 2
    • Jewell N. BriggsJewell N. Briggs 5
    • Elizabeth K. BrockElizabeth K. Brock 7
    • Christopher M. CaubleChristopher M. Cauble 1
    • Matthew L. CutlerMatthew L. Cutler 15
    • Donald J. DaleyDonald J. Daley 1
    • Darin W. DeaverDarin W. Deaver 1
    • Nicholas S. DrysdaleNicholas S. Drysdale 6
    • Monte L. FalcoffMonte L. Falcoff 1
    • Glenn E. ForbisGlenn E. Forbis 11
    • Mark A. Frentrup, Ph.D.Mark A. Frentrup, Ph.D. 3
    • Michael GambleMichael Gamble 1
    • Jason A. HeistJason A. Heist 1
    • Hemant M. KeskarHemant M. Keskar 4
    • Sung Pil KimSung Pil Kim 1
    • Elisabeth A. KoralElisabeth A. Koral 7
    • Damian H. Kotsis, Ph.D.Damian H. Kotsis, Ph.D. 4
    • Kisuk LeeKisuk Lee 1
    • Robert J. LenihanRobert J. Lenihan 1
    • Jeoyuh LinJeoyuh Lin 1
    • Chris K. MillerChris K. Miller 1
    • John E. MunroJohn E. Munro 1
    • Michael R. NyeMichael R. Nye 1
    • Joshua A. PartingtonJoshua A. Partington 2
    • Leanne M. RakersLeanne M. Rakers 15
    • Derek RichmondDerek Richmond 1
    • Douglas A. RobinsonDouglas A. Robinson 15
    • Joel R. SamuelsJoel R. Samuels 10
    • Jeffrey L. SnyderJeffrey L. Snyder 1
    • David L. SuterDavid L. Suter 2
    • Michael L. TaylorMichael L. Taylor 1
    • Jennifer R. TurchynJennifer R. Turchyn 4
    • Michael VarcoMichael Varco 3
    • Joseph E. Walsh, Jr.Joseph E. Walsh, Jr. 1
    • Andrew M. WaxmanAndrew M. Waxman 2
    • Bryan K. WheelockBryan K. Wheelock 15
    • Jennifer M. Woodside WojtalaJennifer M. Woodside Wojtala 11
    • Paul E. Zarek, Ph.D.Paul E. Zarek, Ph.D. 3

  • August 13, 2018

    Trademark Registration – A Vehicle to Protection

    More

  • photo of laboratory and scientist creating biosimilar patents

    August 9, 2018

    FDA Implements Biosimilar Action Plan to Boost Biosimilar Competition

    More

  • image of light bulb to suggest hypothetical biosimilar case study

    August 9, 2018

    At Risk Launch: A Hypothetical Case Study

    More

  • photo of chess pieces representing biosimilar competitive dynamics

    August 8, 2018

    Competitor Influence on the Conduct of the Patent Dance and Litigation

    More

  • photo of biosimilar medications

    August 7, 2018

    Seeking Biosimilar Market Entry When a Competitor is Pursuing Interchangeability: Factors to Consider

    More

  • August 3, 2018

    Undue Process: You Can Ask the USPTO to Review a Patent, but if They Blow it, You may be Powerless to Appeal

    More

June 19, 2017

Missed opportunity: Federal Circuit Again Offers No Clarifying Insight on Alice’s Two-Step Framework

By: Jewell N. Briggs, Associate

April 28, 2017

Ready, Set, Nano-Race!

By: Jennifer M. Woodside Wojtala, Principal

Chemical Patents Image

March 2, 2017

Chemistry & Nanotechnology Developments to Watch in 2017

By: Jennifer M. Woodside Wojtala, Principal; Leanne M. Rakers, Principal

Harness Dickey Biopharma Patent Law

February 9, 2017

2016’s Top Patent and Trade Secret Developments for Chemistry and Nanotechnology

By: Mark A. Frentrup, Ph.D., Principal; David L. Suter, Principal; Jennifer M. Woodside Wojtala, Principal; Jewell N. Briggs, Associate; Damian H. Kotsis, Ph.D., Associate; Jennifer R. Turchyn, Associate

Harness Dickey Biopharma Patent Law

February 9, 2017

USPTO Claim Construction Standards for Inter Partes Review Proceedings

By:

Harness Dickey Biopharma Patent Law

February 9, 2017

USPTO Standards of Review for Inter Partes Review Proceedings

By:

Harness Dickey Biopharma Patent Law

February 9, 2017

USPTO Errs in Failing to Carry Burden to Support Rejection

By:

Harness Dickey Biopharma Patent Law

February 9, 2017

On-Sale Bar for Contractor and Supplier Activities

By: Jennifer M. Woodside Wojtala, Principal; Jason A. Heist, Principal

Harness Dickey Biopharma Patent Law

February 9, 2017

Federal Trade Secrets Act

By: Jennifer M. Woodside Wojtala, Principal; David L. Suter, Principal; Jewell N. Briggs, Associate

Harness Dickey Biopharma Patent Law

February 9, 2017

Enhanced Damages for Willful Infringement

By: Mark A. Frentrup, Ph.D., Principal; Damian H. Kotsis, Ph.D., Associate; Jennifer R. Turchyn, Associate

Stay current

  • Subscribe to our Blogs
  • Twitter
  • Facebook
  • LinkedIn
    • Sitemap
    • Privacy Statement
    • Legal Notice

  • © 2018 Harness, Dickey & Pierce, P.L.C. All rights reserved.